Edit Content
Bizwit-Logo-Final

Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. We have a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. 

Global Pharmaceutical CDMO Market to reach USD 233.62 billion by the end of 2030

Global Pharmaceutical CDMO Market Size study & Forecast, by Product (API, Drug) by Workflow (Clinical, Commercial) by Application (Oncology, Hormonal, Glaucoma, Cardiovascular Disease, Diabetes, Others) and Regional Analysis, 2023-2030

Product Code: HLSHS-52591547
Publish Date: 27-06-2023
Page: 200

Global Pharmaceutical CDMO Market is valued approximately at USD 136.94 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.1% over the forecast period 2023-2030. Pharmaceutical CDMO (Contract Development and Manufacturing Organization) is a type of company that provides outsourced services for the pharmaceutical industry, including drug development, manufacturing, and packaging. CDMOs work on behalf of pharmaceutical companies that do not have the internal resources, expertise, or facilities to undertake certain aspects of drug development or manufacturing.
Numerous causes, such as the rising demand for biopharmaceuticals, improvements in manufacturing technology, and the tendency to outsource medication development and manufacture, are responsible for the expansion. The pharmaceutical industry’s contract development and manufacturing organization (CDMO) market is a crucial one, and its expansion is anticipated to benefit the entire healthcare sector.

The pharmaceutical CDMO market is expected to grow in the future years as a result of the industry’s significant R&D expenditures and the expanding need for biopharmaceuticals. The market for medicines is likely to expand as the ageing population creates new opportunities for drug development. Since they provide pharmaceutical businesses with cost-effective solutions and a shorter time to market through the outsourcing of drug development and production, CDMOs are an essential component of the pharmaceutical industry. In addition, the rise of the biopharma industry, with China emerging as a prominent player, is anticipated to accelerate. Pharmaceutical businesses continually invest in R&D, which is fueling improvements in biopharmaceuticals and the development of fresh therapies and cures. It is anticipated that this pattern would continue, with the top 15 businesses spending a record amount on R&D in 2020. Global pharmaceutical R&D investment is anticipated to increase due to the rising prevalence of chronic diseases and the creation of biosimilars, thus boosting the market’s expansion. In general, the pharmaceutical CDMO future is bright, with several expansion potential opening in the pharmaceutical sector. Additionally, the market is expanding due to the rising incidence of cancer worldwide, which will account for 10 million deaths worldwide in 2021 and be the leading cause of death. It is anticipated that there would be an increase in the demand for innovative cancer therapies, creating opportunities for pharmaceutical and CDMO businesses. In 2020, it is anticipated that the pipeline for oncology medicines in the pharmaceutical sector would make up about 30% of it. With more than 12.5 million new instances of cancer diagnosed each year, the oncology sector is still difficult, time-consuming, and evolving despite the advances in detection and treatment. However, the high cost of Pharmaceutical CDMO stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Pharmaceutical CDMO Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The market is divided into different geographic segments, with Asia Pacific expected to have the quickest CAGR growth throughout the projected period and have the greatest market share in 2022. The APAC region’s market expansion can be attributable to lower manufacturing costs than those in North America and Europe, which makes it a desirable outsourcing hub for the creation of pharmaceuticals. The region’s market is expanding due to the presence of university-affiliated pharmaceutical research hubs and significant funding. Due to favorable legislation and much lower production costs in North America and Europe, India and China are leading the market for contract development and manufacturing organizations.

Major market player included in this report are:
Bushu Pharmaceuticals Ltd.
Nipro Corporation
Thermo Fisher Scientific Inc.
Samsung Biologics
Laboratory Corporation of America Holdings
Siegfried Holding Ag
Catalent, Inc
Lonza Group AG
Recipharm Ab
Piramal Pharma Solutions
Recent Developments in the Market:
Ø In 2020, WuXi AppTec, a Chinese-based Pharmaceutical CDMO, announced the launch of a new digital technology platform to enable end-to-end supply chain management for the pharmaceutical industry.
Ø Some Pharmaceutical CDMOs are adopting sustainability initiatives to reduce their environmental impact. In 2021, Lonza announced its commitment to achieve net-zero greenhouse gas emissions by 2050 and to reduce its carbon footprint by 50% by 2030.

Global Pharmaceutical CDMO Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Product, Workflow, Application, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
API
Drug

By Workflow:
Clinical
Commercial

By Application:
Oncology
Hormonal
Glaucoma
Cardiovascular Disease
Diabetes
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Pharmaceutical CDMO Market, by Region, 2020-2030 (USD Billion)
1.2.2. Pharmaceutical CDMO Market, by Product, 2020-2030 (USD Billion)
1.2.3. Pharmaceutical CDMO Market, by Workflow, 2020-2030 (USD Billion)
1.2.4. Pharmaceutical CDMO Market, by Application, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Pharmaceutical CDMO Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Pharmaceutical CDMO Market Dynamics
3.1. Pharmaceutical CDMO Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing demand for biopharmaceuticals
3.1.1.2. Increasing Cases of Cancer across the Globe
3.1.2. Market Challenges
3.1.2.1. High Cost of Pharmaceutical CDMO
3.1.3. Market Opportunities
3.1.3.1. Technological advancements in manufacturing
Chapter 4. Global Pharmaceutical CDMO Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Pharmaceutical CDMO Market, by Product
5.1. Market Snapshot
5.2. Global Pharmaceutical CDMO Market by Product, Performance – Potential Analysis
5.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
5.4. Pharmaceutical CDMO Market, Sub Segment Analysis
5.4.1. API
5.4.2. Drug
Chapter 6. Global Pharmaceutical CDMO Market, by Workflow
6.1. Market Snapshot
6.2. Global Pharmaceutical CDMO Market by Workflow, Performance – Potential Analysis
6.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Workflow 2020-2030 (USD Billion)
6.4. Pharmaceutical CDMO Market, Sub Segment Analysis
6.4.1. Clinical
6.4.2. Commercial
Chapter 7. Global Pharmaceutical CDMO Market, by Application
7.1. Market Snapshot
7.2. Global Pharmaceutical CDMO Market by Application, Performance – Potential Analysis
7.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
7.4. Pharmaceutical CDMO Market, Sub Segment Analysis
7.4.1. Oncology
7.4.2. Hormonal
7.4.3. Glaucoma
7.4.4. Cardiovascular Disease
7.4.5. Diabetes
7.4.6. Others
Chapter 8. Global Pharmaceutical CDMO Market, Regional Analysis
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Pharmaceutical CDMO Market, Regional Market Snapshot
8.4. North America Pharmaceutical CDMO Market
8.4.1. U.S. Pharmaceutical CDMO Market
8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
8.4.1.2. Workflow breakdown estimates & forecasts, 2020-2030
8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Pharmaceutical CDMO Market
8.5. Europe Pharmaceutical CDMO Market Snapshot
8.5.1. U.K. Pharmaceutical CDMO Market
8.5.2. Germany Pharmaceutical CDMO Market
8.5.3. France Pharmaceutical CDMO Market
8.5.4. Spain Pharmaceutical CDMO Market
8.5.5. Italy Pharmaceutical CDMO Market
8.5.6. Rest of Europe Pharmaceutical CDMO Market
8.6. Asia-Pacific Pharmaceutical CDMO Market Snapshot
8.6.1. China Pharmaceutical CDMO Market
8.6.2. India Pharmaceutical CDMO Market
8.6.3. Japan Pharmaceutical CDMO Market
8.6.4. Australia Pharmaceutical CDMO Market
8.6.5. South Korea Pharmaceutical CDMO Market
8.6.6. Rest of Asia Pacific Pharmaceutical CDMO Market
8.7. Latin America Pharmaceutical CDMO Market Snapshot
8.7.1. Brazil Pharmaceutical CDMO Market
8.7.2. Mexico Pharmaceutical CDMO Market
8.8. Middle East & Africa Pharmaceutical CDMO Market
8.8.1. Saudi Arabia Pharmaceutical CDMO Market
8.8.2. South Africa Pharmaceutical CDMO Market
8.8.3. Rest of Middle East & Africa Pharmaceutical CDMO Market

Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Bushu Pharmaceuticals Ltd.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Nipro Corporation
9.3.3. Thermo Fisher Scientific Inc.
9.3.4. Samsung Biologics
9.3.5. Laboratory Corporation of America Holdings
9.3.6. Siegfried Holding Ag
9.3.7. Catalent, Inc
9.3.8. Lonza Group AG
9.3.9. Recipharm Ab
9.3.10. Piramal Pharma Solutions
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption

At Bizwit Research and Consultancy, we employ a thorough and iterative research methodology with the goal of minimizing discrepancies, ensuring the provision of highly accurate estimates and predictions over the forecast period. Our approach involves a combination of bottom-up and top-down strategies to effectively segment and estimate quantitative aspects of the market, utilizing our proprietary data & AI tools. Our Proprietary Tools allow us for the creation of customized models specific to the research objectives. This enables us to develop tailored statistical models and forecasting algorithms to estimate market trends, future growth, or consumer behavior. The customization enhances the accuracy and relevance of the research findings.
We are dedicated to clearly communicating the purpose and objectives of each research project in the final deliverables. Our process begins by identifying the specific problem or challenge our client wishes to address, and from there, we establish precise research questions that need to be answered. To gain a comprehensive understanding of the subject matter and identify the most relevant trends and best practices, we conduct an extensive review of existing literature, industry reports, case studies, and pertinent academic research.
Critical elements of methodology employed for all our studies include:
Data Collection:
To determine the appropriate methods of data collection based on the research objectives, we consider both primary and secondary sources. Primary data collection involves gathering information directly from various industry experts in core and related fields, original equipment manufacturers (OEMs), vendors, suppliers, technology developers, alliances, and organizations. These sources encompass all segments of the value chain within the specific industry. Through in-depth interviews, we engage with key industry participants, subject-matter experts, C-level executives of major market players, industry consultants, and other relevant experts. This allows us to obtain and validate critical qualitative and quantitative information while evaluating market prospects. AI and Big Data are instrumental in our primary research, providing us with powerful tools to collect, analyze, and derive insights from data efficiently. These technologies contribute to the advancement of research methodologies, enabling us to make data-driven decisions and uncover valuable findings.
In addition to primary sources, we extensively utilize secondary sources to enhance our research. These include directories, databases, journals focusing on related industries, company newsletters, and information portals such as Bloomberg, D&B Hoovers, and Factiva. These secondary sources enable us to identify and gather valuable information for our comprehensive, technical, market-oriented, and commercial study of the market. Additionally, we utilize AI algorithms to automate the collection of vast amounts of data from various sources such as surveys, social media platforms, online transactions, and web scraping. And employ Big Data technologies for storage and processing of large datasets, ensuring that no valuable information is missed during the data collection process.
Data Analysis:
Our team of experts carefully examine the gathered data using suitable statistical techniques and qualitative analysis methods. For quantitative analysis, we employ descriptive statistics, regression analysis, and other advanced statistical methods, depending on the characteristics of the data. This analysis may also incorporate the utilization of AI tools and big data analysis techniques to extract meaningful insights.
To ensure the accuracy and reliability of our findings, we extensively leverage data science techniques, which help us minimize discrepancies and uncertainties in our analysis. We employ Data Science to clean and preprocess the data, ensuring its quality and reliability. This involves handling missing data, removing outliers, standardizing variables, and transforming data into suitable formats for analysis. The application of data science techniques enhances our accuracy, efficiency, and depth of analysis, enabling us to stay competitive in dynamic market environments.
Market Size Estimation:
Our proprietary data tools play a crucial role in deriving our market estimates and forecasts. Each study involves the creation of a unique and customized model. The model incorporates the gathered information on market dynamics, technology landscape, application development, and pricing trends. AI techniques, such as machine learning and deep learning, aid us to analyze patterns within the data to identify correlations, trends, and relationships. By recognizing patterns in consumer behavior, purchasing habits, or market dynamics, our AI algorithms aid us in more precise estimations of market size. These factors are simultaneously analyzed within the model, allowing for a comprehensive assessment. To quantify their impact over the forecast period, correlation, regression, and time series analysis are employed.
To estimate and validate the market size, we employ both top-down and bottom-up approaches. The preference is given to a bottom-up approach, where key regional markets are analyzed as separate entities. This data is then integrated to obtain global estimates. This approach is crucial as it provides a deep understanding of the industry and helps minimize errors.
In our forecasting process, we consider various parameters such as economic tools, technological analysis, industry experience, and domain expertise. By taking all these factors into account, we strive to produce accurate and reliable market forecasts. When forecasting, we take into consideration several parameters, which include:
Market driving trends and favorable economic conditions
Restraints and challenges that are expected to be encountered during the forecast period.
Anticipated opportunities for growth and development
Technological advancements and projected developments in the market
Consumer spending trends and dynamics
Shifts in consumer preferences and behaviors.
The current state of raw materials and trends in supply versus pricing
Regulatory landscape and expected changes or developments.
The existing capacity in the market and any expected additions or expansions up to the end of the forecast period.
To assess the market impact of these parameters, we assign weights to each one and utilize weighted average analysis. This process allows us to quantify their influence on the market and derive an expected growth rate for the forecasted period. By considering these various factors and applying a weighted analysis approach, we strive to provide accurate and reliable market forecasts.
Insight Generation & Report Presentation:
After conducting the research, our experts analyze the findings in relation to the research objectives and the specific needs of the client. They generate valuable insights and recommendations that directly address the client’s business challenges. These insights are carefully connected to the research findings to provide a comprehensive understanding.
Next, we create a well-structured research report that effectively communicates the research findings, insights, and recommendations to the client. To enhance clarity and comprehension, we utilize visual aids such as charts, graphs, and tables. These visual elements are employed to present the data in an engaging and easily understandable format, ensuring that the information is accessible and visually appealing to the client. Our aim is to deliver a clear and concise report that conveys the research findings effectively and provides actionable recommendations to meet the client’s specific needs.

Need Assistance

Contact Person -
Krishant Mennon
Call us @
+ 91 99931 15879
Email: sales@bizwitresearch.com

Checkout

Why Choose Us?

Quality over Quantity

Backed by 60+ paid data sources our reports deliver crisp insights with no compromise quality.

Analyst Support

24x7 Chat Support plus
free analyst hours with every purchase

Flawless Methodology

Our 360-degree approach of market study, our research methods leave stones unturned.

Enquiry Now